Navigation Links
BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report
Date:3/19/2012

li>
  • Launch of BREAKYL in Europe.  BDSI expects its commercial partner, Meda, to launch BREAKYL (brand name for ONSOLIS in the E.U.) in the E.U. during the second half of 2012, which would result in a milestone payment to BDSI of $5 million.
  • Reformulation of ONSOLIS for U.S. Market.  BDSI will work with FDA and Meda to address the appearances issues noted by FDA with the aim of re-launching the product in the U.S. under a class-wide REMS program.  BDSI will provide updates on the timing for these efforts as information is available.
  • "We look forward to another exciting year ahead and thank our shareholders for their continued support," said Dr. Sirgo.  "Our product pipeline is strong as we move into 2012, behind the aggressive development of BEMA Buprenorphine and BNX in the substantial and growing pain and opioid dependence markets.  Our licensing deal with Endo offers great promise for the future of BEMA Buprenorphine and its role in the treatment of chronic pain, and we continue to believe that there remains significant upside potential in the treatment of opioid dependence, where we have the opportunity to be the next branded transmucosal buprenorphine/naloxone product to reach the rapidly growing opioid dependence market.  We believe there is a significant opportunity to enhance the value of the company this year behind the continued progress of our key assets, BEMA Buprenorphine and BNX."

    About BioDelivery Sciences International

    BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient nee
    '/>"/>

    SOURCE BioDelivery Sciences International, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
    2. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
    3. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
    4. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
    5. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
    6. BioDelivery Sciences Provides Update on Status of Modified REMS Program for ONSOLIS
    7. BioDelivery Sciences to Present at the Jeffries Global Healthcare Conference
    8. BioDelivery Sciences Announces Commercial Launch of ONSOLIS in Canada
    9. BioDelivery Sciences Announces Upcoming Presentations at Three Investor Conferences
    10. BioDelivery Sciences Announces Positive Results Supporting BEMA Buprenorphine/Naloxone Formulation for Opioid Dependence
    11. Samuel J. Sears, Jr. Appointed to BioDelivery Sciences Board of Directors
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... and SPARTANBURG, South Carolina , ... Research Network and Molecular Health have announced a collaboration ... diagnostic decision support to the majority of cancer patients ... Network will collaborate with Molecular Health to harness the ... identify cohorts from hundreds of thousands of patients to ...
    (Date:5/29/2015)... 2015 Research and Markets ... the "Surgical/Operating Microscopes Market by Application & ... report to their offering.      (Logo: ... is poised to reach $806.6 million by 2020 ... of 12.3% from 2015 to 2020. , ,Major ...
    (Date:5/29/2015)... and MENLO PARK, Calif. ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... and commercializing proven cancer therapies in new orphan ... American Association of Cancer Research (AACR) Advances ... potential for its lead product candidate VAL-083 ...
    Breaking Medicine Technology:New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 2New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 3New Collaboration to Dramatically Expand Therapeutic Clinical Trial Access for Cancer Patients Across the United States 4Surgical/Operating Microscopes Market by Application & End User - Global Forecast to 2020 for the $806 Million Industry 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
    ... Nov. 28, 2011 The most common poisons that threaten ... acetaminophen, antidepressants, and ADHD medications. Any medication, even those prescribed ... cats that might eat whatever they find. For ... Program and the American Veterinary Medical Association (AVMA) ...
    ... & Johnson (NYSE: JNJ ) will participate in the ... Nov. 29 th at The New York Palace, New York, ... session scheduled at 8:00 a.m. (Eastern Time). The ... accessing the Johnson & Johnson website at www.investor.jnj.com . ...
    Cached Medicine Technology:Sea Grant and AVMA Join Forces to Raise Awareness on Medicine Disposal 2
    (Date:5/29/2015)... The Recovery Village at Palmer ... co-occurring mental health treatment facility, will host a ... general public on June 1st, and will begin ... at Palmer Lake will offer affordable detox, residential, ... and evidence-based therapies, in a luxurious setting designed ...
    (Date:5/29/2015)... 2015 Red Hot & Blue Restaurants ... Hot & Blue restaurant at 525 New Waverly Place in ... 2015. “The Red Hot & Blue Restaurant was previously located ... we have moved to a new location in the center,” ... of all the activities on the Promenade–with outdoor seating and ...
    (Date:5/29/2015)... May 29, 2015 A group of doctors ... joined the national effort to teach this “new math” to ... U.S. have been “sickened” by the recent implementation of Common ... or hate it, Common Core is now a reality in ... Parents are now seeking ways to improve common core ...
    (Date:5/29/2015)... Mediaplanet has joined forces with Raw Elements ... importance of proper sun protection. The print component of ... circulation of approximately 250,000 copies and an estimated readership ... through a vast social media strategy, and across a ... explore the digital version of the campaign, click ...
    (Date:5/29/2015)... 29, 2015 Healthpointe is now ... specialists, physical therapy, and injections , For patients ... and/or lower back pain, Healthpointe has a team ... herniated discs, disc protrusions and other causes of ... Healthpointe’s team of renowned surgeons are now treating ...
    Breaking Medicine News(10 mins):Health News:Advanced Recovery Systems Announces the Opening of The Recovery Village at Palmer Lake 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 2Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 3Health News:Red Hot & Blue Restaurant Opens in Cary, North Carolina 4Health News:Doctors Discover a Cure for the Common Core 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 2Health News:Healthpointe’s Pain Management Specialists Now Providing Lumbar Epidural Injections in Los Angeles County 3
    ... should be made aware, researcher says , , WEDNESDAY, ... twins, those conceived through assisted reproductive technology (ART) are ... intensive care, finds a new study. , Researchers analyzed ... Western Australia between 1994 and 2000. , "We found ...
    ... Outlines Possible Ways to Improve CBO Modeling and ... a Partnership to Fight Chronic Disease policy briefing ... O,Grady, Ph.D., and James C. Capretta, M.A., released ... and other Chronic Diseases: The Current Context and ...
    ... Mercy Hospital Indicator of Demand for Well-Priced New ... May 21 Despite numerous negative earnings announcements, ... equipment appears to be robust during the current ... new and refurbished ultrasound solutions, reported a 118 ...
    ... America, Inc. (OTC Bulletin Board: CPCF.OB), announced today the ... for specific application to the MedClose(TM) VCS. CPC ... MedClose(TM) VCS, which is an internal puncture-closing system for ... In addition, CPC is focused on the development of ...
    ... Health, Inc. (Nasdaq: GHDX ) today announced ... at the American Society of Clinical Oncology (ASCO) Annual ... at the Orange County Convention Center in Orlando, Florida. ... DX(R) breast cancer test, which is clinically validated to ...
    ... Company Reports Improved Operating Results, Strengthened Balance SheetTo ... 11 a.m. Eastern Time Today SANTA MONICA, Calif., ... Bulletin Board: CBAI), the umbilical cord blood stem ... bringing the life saving potential of stem cells ...
    Cached Medicine News:Health News:Fertility Treatment Twins More at Risk for Hospitalizations 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 2Health News:National Coalition Hosts Event to Examine Costs Projections for Chronic Diseases 3Health News:MedPro Imaging Reports 118 Percent Growth For First Quarter 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 2Health News:CPC Files Patent for Synthetic Sealant for the MedClose(TM) Vascular Closure System (VCS) 3Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 2Health News:Genomic Health to Present Multiple New Studies at the American Society of Clinical Oncology Annual Meeting 3Health News:Cord Blood America, Inc. Announces 2009 First Quarter Results 2Health News:Cord Blood America, Inc. Announces 2009 First Quarter Results 3Health News:Cord Blood America, Inc. Announces 2009 First Quarter Results 4
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: